【摘要】 目的:观察多西他赛与吉西他滨(DG)、多西他赛与顺铂(DP)、吉西他滨顺铂(GP)方案一线治疗晚期非小细胞肺癌的临床疗效和不良反应。方法:将150例患者分为三组,DG组:多西他赛75mg/m2,d1,吉西他滨1g/m2,d1,8。DP组:多西他赛用法同上,顺铂75mg/m2,d1-3;GP组:吉西他滨和顺铂用法同上。化疗每三周重复,每周期评价不良反应、生活质量,两周期后评价疗效并随访生存期。结果:DG组有效率为45.8%,1年生存率45%,3年生存率9.6%;DP组组有效率为46.2%,1年生存率47%,3年生存率9.9%;GP组组有效率为42%,1年生存率47.5%,3年生存率9.6%(P>0.05)。三组主要毒副作用为骨髓抑制、恶心、呕吐、脱发。结论:DP与GP方案仍是晚期NSCLC的标准一线治疗方案。更多还原

【Abstract】 Objective:To compare the efficacy and safety of docetaxel/gemcitabine,docetaxel/cispatin and gemcitabine/cispatin regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 150 patients with advanced NSCLC were divided into 3 groups.The patients received docetaxel 75mg/m2 on day 1 and gecitabine 1g/m2 on day 1 and 8 in DP groups.Patients received docetaxel 75mg/m2 on day 1 and cispatin 75mg/m2 on day 1 to day 3 in the DP and GP groups.The treatment schedule was recycled every 3 weeks.The toxicity and quality of life were evaluated after every cycle.The treatment response and survival rate were evaluated by the end of two cycles.Results:The response rates of DG,DP and GP group were 45.8%,46.2% and 42%,respectively.Comparing the three groups,1 and 3 year survival rates were 45%,9.6% and 47% and 9.9%,47.5% and 9.6%,respectively(P>0.05).The main side-effects were myelosuppression,nausea,vomiting and Alopecia.Conclusion:DP and GP were well toleranced in advanced NSCLC patients.更多还原